Suppression of the TRIF-dependent signaling pathway of Toll-like receptor by CDr10b in RAW264.7 macrophages

Toll-like receptors (TLRs) recognize distinct pathogen-associated molecular patterns and play a critical role in innate immune responses. TLR signaling pathways can be largely classified as either myeloid differential factor 88 (MyD88)- or toll-interleukin-1 receptor domain-containing adapter induci...

Full description

Saved in:
Bibliographic Details
Published in:International immunopharmacology 2015-09, Vol.28 (1), p.29-33
Main Authors: Gu, Gyo-Jeong, Ahn, Sang-il, Kim, Ji-Soo, Hong, Chae-Yeon, Lee, Sung-Chan, Chang, Young-Tae, Choi, Tae Hyun, Kim, Byoung Soo, Youn, Hyung-Sun
Format: Article
Language:English
Subjects:
Adaptor Proteins, Vesicular Transport - drug effects
Animals
Boron Compounds - chemical synthesis
Boron Compounds - pharmacology
CDr10b
Chemokine CXCL10 - biosynthesis
Cyclooxygenase 2 - drug effects
Interferon Regulatory Factor-3 - biosynthesis
Interferon Regulatory Factor-3 - genetics
IP-10
IRF3
Macrophages - drug effects
Mice
NF-kappa B - drug effects
Nitric Oxide Synthase Type II - drug effects
Protein-Serine-Threonine Kinases - biosynthesis
Protein-Serine-Threonine Kinases - genetics
RAW 264.7 Cells
Signal Transduction - drug effects
Toll-like receptor
Toll-Like Receptor 3 - agonists
Toll-Like Receptor 4 - agonists
Toll-Like Receptors - antagonists & inhibitors
TRIF
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Toll-like receptors (TLRs) recognize distinct pathogen-associated molecular patterns and play a critical role in innate immune responses. TLR signaling pathways can be largely classified as either myeloid differential factor 88 (MyD88)- or toll-interleukin-1 receptor domain-containing adapter inducing interferon-β (TRIF)-dependent pathways. Compound of Designation red 10 binding (CDr10b) was synthesized to investigate its role in neuroinflammatory diseases. This study was conducted to determine whether CDr10b can affect TLR signaling pathways. CDr10b suppressed NF-κB activation as well as COX-2 and iNOS expression induced by TLR3 or TLR4 agonists. CDr10b also suppressed the activation of interferon regulatory factor 3 (IRF3) and the expression of interferon inducible protein-10 (IP-10) induced by TLR3 or TLR4 agonists. These results indicate that CDr10b can modulate the TRIF-dependent pathway of TLRs and has the potential to become a new therapeutic drug for chronic inflammatory diseases. •Inflammation is involved in numerous diseases.•Toll-like receptors (TLR) play a significant role in the induction of innate immune responses•Compound of Designation red 10 binding (CDr10b) was synthesized.•CDr10b inhibited the IRF3 activation and IP-10 expression induced by TLR3 or TLR4 agonists.•These results suggest that CDr10b can be developed as a potent anti-inflammatory drug.
ISSN:1567-5769
1878-1705
DOI:10.1016/j.intimp.2015.05.017